ARS Pharmaceuticals (SPRY) Income towards Parent Company (2020 - 2026)

ARS Pharmaceuticals has reported Income towards Parent Company for 7 years, with the latest figure at -$95.9 million in Q1 2026.

• Quarterly Income towards Parent Company fell 156.94% year-over-year to -$95.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$474.7 million (down 122.98% YoY) and the FY2025 annual result came in at -$171.3 million, down 2241.76% from the prior year.
• Income towards Parent Company declined to -$95.9 million in Q1 2026 per SPRY's latest filing, from -$43.5 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $47.3 million in Q4 2024 and troughed at -$39.4 billion in Q1 2023.
• A 5-year average of -$5.5 billion and a median of -$67.4 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2024: Income towards Parent Company plunged 339646.93% in 2023, then jumped 571.87% in 2024.
• Over 5 years, Income towards Parent Company stood at -$15.1 million in 2022, then jumped by 33.83% to -$10.0 million in 2023, then surged by 571.87% to $47.3 million in 2024, then sank by 192.08% to -$43.5 million in 2025, then tumbled by 120.44% to -$95.9 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$95.9 million, -$43.5 million, and -$113.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.